VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia Care | DelveInsight [Yahoo! Finance]
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: Yahoo! Finance
With an estimated 128 million Americans affected by presbyopia, VUITY offers a convenient, non-invasive alternative to reading glasses. Its adoption could expand as awareness rises and consumers seek lifestyle-friendly vision correction options. LAS VEGAS March 26, 2025 /PRNewswire/ -- DelveInsight's " VUITY Market Size, Forecast, and Market Insight Report " highlights the details around VUITY, which is a miotic, 1.25% pilocarpine hydrochloride ophthalmic solution prescribed to treat presbyopia in adults. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of VUITY. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [ the United Sta
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its price target raised by analysts at Citigroup Inc. from $44.00 to $47.00. They now have a "buy" rating on the stock.MarketBeat
- LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire
- LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at TD Cowen. They set a "buy" rating and a $60.00 price target on the stock.MarketBeat
LENZ
Earnings
- 3/19/25 - Miss
LENZ
Sec Filings
- 3/27/25 - Form SCHEDULE
- 3/19/25 - Form S-8
- 3/19/25 - Form 10-K
- LENZ's page on the SEC website